Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

n and our financial performance.

Our actual results may vary depending on a variety of factors, including:

  • the development of competitive generic versions of oral Vancocin;
  • our ability to successfully commercialize Cinryze;
  • our ability to receive regulatory approval for the use of Cinryze for the acute treatment of HAE;
  • the availability of third party payer reimbursement for Cinryze patients;
  • our ability to develop a clinical development program for maribavir;
  • approval of products which are currently marketed for other indications by other companies or new pharmaceuticals and technological advances to treat the conditions addressed by Vancocin or Cinryze;
  • fluctuations in wholesaler order patterns and inventory levels;
  • manufacturing, supply or distribution interruptions, including but not limited to our ability to acquire adequate supplies of Vancocin and Cinryze to meet demand for the product;
  • changes in prescribing or procedural practices of physicians, including off-label prescribing of products competitive with Vancocin and Cinryze;
  • the timing of regulatory submissions and approvals;
  • actions by the FDA, EMEA and the Internal Revenue Service or other government regulatory agencies;
  • decreases in the rate of infections for which Vancocin is prescribed or decreases in the sensitivity of the relevant bacteria to Vancocin;
  • an impairment of our intangible assets if our market capitalization remains less than our book value;
  • the timing and results of anticipated events in our clinical development programs; and
  • the timing and nature of potential business development activities related to our efforts to expand our current portfolio through in-licensing or other means of acquiring produ
    '/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 2014 During his lifetime Richard L. ... to surround himself with great people and take risks ... friends often marveled at his extraordinarily courageous attitude when ... and -- even with his death impending—that’s how he ... that would ultimately take his life. , Carrying on ...
(Date:11/22/2014)... CannLabs, Inc. (OTCQB: CANL), the ... testing methodologies relating to cannabis, today announced that it ... credit from an existing stockholder of the Company. ... commitment from one of our existing stockholders,” stated ... will help accelerate our planned expansions into the Connecticut ...
(Date:11/22/2014)... On November 17th Chicago start-up Briteseed outperformed 137 ... Summit in San Francisco to take first place in ... Valley investors and technology elites as the premier showcase ... Briteseed to move on to the final phase ... with other elite innovation finalists for a $125,000 cash ...
(Date:11/22/2014)... 22, 2014 Respiratory therapy students ... proper management of life-like respiratory ailments using the ... . Grand Rapids-based, Michigan Instruments Inc. developers of ... of the respiratory simulation units to the pro-gram, ... Valley and Muskegon Community College are collaborating to ...
Breaking Biology Technology:Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3CannLabs Secures $750,000 Line Of Credit 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3
... Echeverri, Christoph Sachse, , ... David Brown Ambion, Inc. , ... tool for understanding gene function. It is ... short double-stranded RNAs called short interfering , ...
... RNase activity varies dramatically across , ... mouse tissues showed that total RNase activity spans a 181,000-fold ... the level of RNase , control required for successful RNA ... Figure 1. , Quantitative Hierarchy ...
... to design the dsRNA that , most efficiently ... length correlate with silencing efficiency? Ambion scientists , ... dsRNA of different sizes and directed , ... (Figure 1A), were prepared using the MEGAscript RNAi Kit , ...
Cached Biology Technology:siRNA Design: It's All in the Algorithm 2siRNA Design: It's All in the Algorithm 3siRNA Design: It's All in the Algorithm 4siRNA Design: It's All in the Algorithm 5siRNA Design: It's All in the Algorithm 6siRNA Design: It's All in the Algorithm 7siRNA Design: It's All in the Algorithm 8siRNA Design: It's All in the Algorithm 9siRNA Design: It's All in the Algorithm 10RNase Activity in Mouse Tissue: Classification, Hierarchy, and Methods for Control 2RNase Activity in Mouse Tissue: Classification, Hierarchy, and Methods for Control 3RNAi: Size Does Matter 2
(Date:11/4/2014)... , November 4, 2014   ... vertical market growth   Fuel3D , a ... closed a funding round totaling $6.4 million (£4 million). This ... funding secured earlier this year and paves the way for ... 2015. The funding round was led by Chimera ...
(Date:11/4/2014)... , Nov. 4, 2014   Neurotechnology ... today announced that the latest version of its ... the Ongoing MINEX evaluation organized by ... fingerprint algorithms using the INCITS 378 fingerprint standard ... requirement in public tenders in the ...
(Date:11/3/2014)... of Colorado Cancer Center study published in ... Sciences describes the activity of a recently discovered ... or IL-37. It has been known to limit inflammation ... adaptive immune system: IL-37 inhibits the ability of the ... "Knowing this mechanism that underlies IL-37,s effect on the ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... irritable bowel syndrome has been traced to a small piece ... leading to hostile conditions that can produce diarrhea, bloating and ... segment sends signals that stop the activity of the gene ... a shortage of glutamine in the gut with the seepage ...
... since their ill-fated attempt to climb Everest over 80 ... they have discovered another important part of the puzzle ... returned from their pioneering expedition. The research, published in ... newly uncovered historical data collected during their expedition to ...
... led by the Georgia Institute of Technology has been ... Foundation and the National Aeronautics and Space Administration to ... of how life started on Earth. Researchers will focus ... spontaneous formation of functional polymers -- such as proteins ...
Cached Biology News:Scientists target possible cause of 1 form of bowel disease 2Scientists target possible cause of 1 form of bowel disease 3Mallory and Irvine: Did extreme weather cause their disappearance? 2Georgia Tech awarded a $20M Center for Chemical Innovation from NSF and NASA 2Georgia Tech awarded a $20M Center for Chemical Innovation from NSF and NASA 3
Wellpro 96 an automated liquid handling system for 96-well plates that quickly and accurately prepares large quantities of serial dilutions. The Wellpro also performs plate to plate transfers using ...
...
... 45° Fixed Angle rotor for ... CL2, Centra CL3/CL3R, HN-SII or ... style rotor accepts 15 mL ... disposable conical tubes as well ...
...
Biology Products: